Multifocal intraocular lens exchange by a different multifocal technology in patients with neuroadaptation failure: clinical outcomes and patient satisfaction

Session Details

Session Title: Multifocal IOLs II

Session Date/Time: Monday 16/09/2019 | 08:30-10:30

Paper Time: 10:14

Venue: Free Paper Forum: Podium 1

First Author: : J.Alió SPAIN

Co Author(s): :    O. Al-Shymali   C. McAlinden                          

Abstract Details

Purpose:

To report the clinical and visual outcomes, subjective change in quality of vision, visual function and satisfaction in a series of cases in which multifocal intraocular lenses (MF-IOLs) were exchanged with another multifocal technology due to neuroadaptation failure.

Setting:

Vissum, Ophthalmology Institute of Alicante, Alicante, Spain. Division of Ophthalmology, Miguel Hernández University, Alicante, Spain

Methods:

This is a Case series including 26 eyes of 15 patients that underwent explantation of a MF-IOL followed by an implantation of another MF-IOL of a different optical technology. Validated questionnaires were used to assess quality of vision, visual function and satisfaction before and after the multifocal IOL exchange. The questionnaires were the Quality of Vision (QoV) questionnaire, the Visual Function Index-14 (VF-14) and a satisfaction questionnaire. The main outcome measures were the change in subjective quality of vision, visual function, and satisfaction, and the secondary visual outcomes were refractive and visual outcomes.

Results:

MF IOL exchange was successful with no significant complications. The mean time explantation-implantation was 12 months. Quality of vision improved with a pre-exchange QoV score of 55±23.13 to post-exchange of 37.6±28.84 (P=0.041) [Frequency subscale]. Visual function improved with a change in VF-14 score from 58.02±22.74 to 87.3±15.04 (P=0.001). For satisfaction, 80% of patients reported they would repeat the procedure. The mean uncorrected distance visual acuity (UDVA) improved significantly from 20/35 to 20/26.5 after the exchange (P=0.015). The corrected distance visual acuity (CDVA) improved from 20/27 to 20/21.5 (P=0.001). Safety and efficacy indices reached 1.26 and 1.02.

Conclusions:

MF-IOL exchange with a different MF-IOL technology in patients with neuroadaptation failure improves quality of vision, visual function, satisfaction and visual and refractive parameters.

Financial Disclosure:

None